104 related articles for article (PubMed ID: 20639123)
21. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
22. [Application of dendritic cells in clinical tumor therapy].
Li Y; Xian LJ
Ai Zheng; 2002 Apr; 21(4):443-6. PubMed ID: 12452029
[TBL] [Abstract][Full Text] [Related]
23. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
[TBL] [Abstract][Full Text] [Related]
24. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
25. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.
de Pillis LG; Gu W; Radunskaya AE
J Theor Biol; 2006 Feb; 238(4):841-62. PubMed ID: 16153659
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cells in cancer immunotherapy.
Gunzer M; Grabbe S
Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
28. Development of vaccines against self-antigens: the p53 paradigm.
Chada S; Mhashilkar A; Roth JA; Gabrilovich D
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
[TBL] [Abstract][Full Text] [Related]
29. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
30. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
[TBL] [Abstract][Full Text] [Related]
31. Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas.
Cho DY; Lin SZ; Yang WK; Hsu DM; Lee HC; Lee WY; Liu SP
Cell Transplant; 2009; 18(9):977-83. PubMed ID: 19523342
[TBL] [Abstract][Full Text] [Related]
32. Modeling multi-drug chemotherapy: tailoring treatment to individuals.
Gardner SN
J Theor Biol; 2002 Jan; 214(2):181-207. PubMed ID: 11812172
[TBL] [Abstract][Full Text] [Related]
33. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells.
Liu Y; Chiriva-Internati M; You C; Luo R; You H; Prasad CK; Grizzi F; Cobos E; Klimberg VS; Kay H; Mehta JL; Hermonat PL
Cancer Gene Ther; 2005 Mar; 12(3):304-12. PubMed ID: 15565181
[TBL] [Abstract][Full Text] [Related]
34. Tumor-dendritic cell fusion technology and immunotherapy strategies.
Shu S; Cohen P
J Immunother; 2001; 24(2):99-100. PubMed ID: 11265778
[No Abstract] [Full Text] [Related]
35. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model.
Cappuccio A; Elishmereni M; Agur Z
Cancer Res; 2006 Jul; 66(14):7293-300. PubMed ID: 16849579
[TBL] [Abstract][Full Text] [Related]
36. Clinical applications of dendritic cell vaccines.
Morse MA; Lyerly HK
Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
[TBL] [Abstract][Full Text] [Related]
37. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
38. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy with dendritic cells for cancer.
Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
